Additionally, we observed high PDL1% values in our sample (median of 60%) and this may also account to a long disease progression as PDL1% is associated with improved survival even when using monotherapy agents in advanced non-small-cell lung cancer. This evidence concerns the gene CD274 and non-small cell lung carcinoma.